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is key to the pathogenesis of many age-related degenerative diseases. We describe here for the Alzheimer’s disease-related
amyloid b peptide (Ab) an investigation of the sequence-based determinants of the balance between the formation of preﬁbrillar
aggregates and amyloid ﬁbrils. We show that by introducing single-point mutations, it is possible to convert the normally harmless
Ab40 peptide into a pathogenic species by increasing its relative propensity to form preﬁbrillar but not ﬁbrillar aggregates, and,
conversely, to abolish the pathogenicity of the highly neurotoxic E22G Ab42 peptide by reducing its relative propensity to form
preﬁbrillar species rather than mature ﬁbrillar ones. This observation can be rationalized by the demonstration that whereas
regions of the sequence of high aggregation propensity dominate the overall tendency to aggregate, regions with low intrinsic
aggregation propensities exert signiﬁcant control over the balance of the preﬁbrillar and ﬁbrillar species formed, and therefore
play a major role in determining the neurotoxicity of the Ab peptide.INTRODUCTIONIn addition to their familiar compact and frequently highly
intricate native folds, proteins can adopt a second, highly
ordered conformation, the amyloid fibril, whose core struc-
ture is an array of b-strands oriented perpendicular to the
fibril axis (1). This alternative structure is frequently stable
over a range of solution conditions, and its formation appears
to be a consequence of the intrinsic character of the polypep-
tide backbone (2,3). Although the ability to form amyloid
fibrils is a generic property shared by many, if not all,
peptides and proteins, the propensity to aggregate in this
way can vary dramatically from one to another, and is deter-
mined by the physicochemical properties of the amino acid
side chains that are present in a given sequence (4). Indeed,
it is possible to use these physicochemical properties to
predict the propensity of given polypeptide sequences to
aggregate, even under conditions where they normally adopt
three-dimensional folds (5,6).
Although there is increasing evidence that amyloid struc-
tures have a functional role in a variety of organisms (7), the
formation of misfolded amyloid fibrils in humans appears
at present to be primarily associated with disease states.
These include many of the most common and most devas-
tating neurodegenerative disorders, such as Alzheimer’s
disease (AD), Parkinson’s disease, and Huntington’s disease.
The detailed pathogenesis of these diseases is not yet fullySubmitted October 27, 2009, and accepted for publication December 23,
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0006-3495/10/04/1677/8 $2.00defined, but there is increasing evidence that the oligomeric
prefibrillar precursors of amyloid fibrils may in fact be highly
toxic, whereas the fibrils themselves are likely to be rela-
tively harmless and their formation could indeed be protec-
tive in some cases (8–10).
One of the most intensively investigated amyloid-associ-
ated neurodegenerative disorders is AD. In this condition,
fibrils consisting of the amyloid b (Ab) peptide are deposited
in extracellular plaques in the cortex of the brain. Many
studies, however, have shown that such plaques can also
be present in the absence of clinical signs of dementia
(11,12), and that the extent of plaque formation correlates
only poorly with cognitive dysfunction in animal models
of Ab (13). Recent studies have instead implicated a variety
of aggregated forms of Ab as causes of cognitive dysfunc-
tion and neurodegeneration in AD. These range in size
from dimers to much larger soluble oligomers (13,14), which
are known to be populated before fibril formation occurs.
Because of their likely role in pathogenesis, it is important
to understand how the intrinsic properties of peptides and
proteins such as Ab determine their relative propensities to
form these differentially toxic types of aggregates.
To elucidate the relationship between Ab aggregation and
neurodegeneration, in a previous study we performed a
systematic analysis using site-specific mutagenesis of Ab
neurotoxicity in a Drosophila model of AD (15). Our
strategy is to rationally design mutations using an algorithm
that can identify the effects of such mutations on the propen-
sity of Ab to aggregate into fibrils or prefibrillar aggregates.
Using this approach, we identified several mutations that
profoundly alter the neurotoxicity of Ab in vivo but are
not, on the basis of our predictions, expected to significantlydoi: 10.1016/j.bpj.2009.12.4320
1678 Brorsson et al.influence its propensity to aggregate into fibrils. We sug-
gested, however, that such differences in neurotoxicity could
be attributable to changes in the computationally determined
propensities of these mutant Ab peptides to form the
moretoxic prefibrillar aggregates before the formation of
the potentially benign fibrils. In the study presented here,
we set out to test this hypothesis experimentally by under-
taking a kinetic and morphological comparison of the
in vitro aggregation of two pairs of peptides. Although
each pair differs by only a single amino acid, and they have
very similar predicted propensities to form b-sheet-rich
amyloid, they have also been found to have dramatically
different neurodegenerative effects in a Drosophila model
of AD. The results reveal that the single-point mutations con-
cerned do indeed substantially alter the propensity of Ab to
form prefibrillar aggregates in vitro, strongly supporting the
hypothesis that it is these species that give rise to the neuronal
degeneration observed in vivo. Furthermore, we show that
we can rationalize these effects by examining the biophysical
and physicochemical properties of the various mutant Ab
peptides, and gain new insights into the specific determinants
of prefibrillar and fibrillar aggregate formation.MATERIALS AND METHODS
Preparation of the Ab peptides
The Ab peptides Ab40, Ab42, E22G Ab42, I31E/E22G Ab42, and E3R Ab40
were purchased from Bachem (Weil am Rhein, Germany) dissolved in tri-
fluoroacetic acid, and sonicated for 30 s on ice. The trifluoroacetic acid
was removed by lyophilization, and the peptides were then dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol and divided into aliquots that were dried
by rotary evaporation at room temperature. The amount of peptide in the
individual aliquots was determined by quantitative amino acid analysis.
Thioﬂavin T ﬂuorescence measurement
The peptides were dissolved at a concentration of 30 mM in 50mMNaH2PO4
(pH 7.4) and incubated at 29C with continuous agitation at 1000 rpm.
At regular time intervals, 5 mL aliquots of the peptide solution were removed
and added to 100 mL of 20 mM thioflavin T (ThT) in 50 mM Gly-NaOH
(pH 8.5). Fluorescence intensity was measured using an excitation wave-
length of 440 nmand an emissionwavelength of 480 nmon aBMGFLUOstar
OPTIMA fluorimeter (BMG Labtech, Aylesbury, UK). The rate of aggrega-
tion (k) in each case was determined by fitting the growth phase of fluores-
cence intensity as a function of time to a single exponential function: y ¼
q þ Ae(kt). Each kinetic experiment was repeated three to five times, and
the traces shown in the figures are from a representative experiment.
Size exclusion chromatography
Size exclusion chromatography (SEC) was carried out using an
AKTAexplorer (GE Healthcare, Little Chalfont, UK) with a Superdex 200
5/150 GL column (GE Healthcare) operated at 4C with 0.6% Tween-20
in phosphate-buffered saline (PBS) flowing at 0.3 mL/min. The peptides
that eluted from the column were detected by monitoring changes in absorp-
tion intensity at 214 nm. The Ab peptides were initially dissolved in 10 mM
NaOH at a concentration of ~1 mg/mL, sonicated for 5 min, and stored at
80C until required. Peptide solutions were diluted to a concentration of
30 mM in 50 mM PBS buffer, and then diluted with 2.4% Tween-20 in
50 mM PBS to a final concentration of 0.6% Tween-20. Diluted solutionsBiophysical Journal 98(8) 1677–1684were vortexed for 5 s to generate thorough mixing, and 40 mL aliquots were
loaded onto the column immediately. Five replicate chromatograms were
collected for each peptide, and background effects were corrected for by
subtracting the chromatogram of 0.6% Tween-20 in PBS. The amount of
peptide in each peak was determined by measuring the peak areas in
the chromatogram using the calculated extinction coefficient of Ab42 of
92,800 M1cm1 at 214 nm.
Transmission electron microscopy
For transmission electron microscopy (TEM), the peptides were dissolved at
a concentration of 30mM in 50mMNaH2PO4 (pH 7.4) and incubated at 25
C
without any agitation beyond that needed for initial mixing. Samples were
applied to formvar/carbon-coated copper grids, stained with 2% (w/v) uranyl
acetate, and viewed in a Philips CEM100 transmission electron microscope.
Generation of transgenic fruit ﬂies
Mutant Ab42 expression constructs were produced by site-directed mutagen-
esis of the wild-type (WT) Ab42 sequence in the pMT vector (Invitrogen,
Paisley, UK) and subcloned into the pUAST vector. Transgenic fruit flies
expressing the desired Ab42 variants were generated according to the proce-
dures described by Crowther et al. (16).
Survival assays
Survival assays were carried out as described previously (15). Survival
curves were calculated using Kaplan-Meier plots, and differences between
the curves were analyzed using the log rank method. For previously charac-
terized transgenic lines expressing Ab40, Ab42, or E22G Ab42, the survival
of one representative line was measured. For the novel mutational variants
E3R Ab40 and I31E/E22G Ab42, six independent lines were analyzed
(n¼ 100 for each line) to control for variability in expression levels between
individual lines due to the varying location of transgene insertion. The rela-
tive reductions in median survival for Ab transgenic flies (Stox) were calcu-
lated relative to Ab40 transgenic flies as Stox ¼ (median survival Ab40 
median survival Abmut)/median survival Ab40.
Calculation of aggregation propensities
The propensity to form b-sheet-rich amyloid aggregates (Zagg) was calcu-
lated as described previously (5). Briefly, for a given protein, Zagg was
obtained by averaging the propensities that were above zero in the aggrega-
tion profile of the sequence. All of the propensities were then normalized to
generate a variable with an average value of zero and a standard deviation of
1.0 (the normalization is made by calculating the propensities of a set of
random sequences). An aggregation profile can contain residues with
a propensity larger than 1.0, but these cases are usually sparse and their
contribution is diluted upon averaging over the sequence. Consequently,
sequences with an overall Zagg score larger than 1.0 are very rare. To calcu-
late the propensity for forming prefibrillar aggregates (Zpf), we used an
approach (15) based on an equation containing the same physicochemical
contributions used to calculate Zagg, but with specific weights determined
using a set of experimentally determined prefibrillar aggregation rates for
the protein acylphosphatase (18). A Web server for calculating Zagg and
Zpf is available at http://www-vendruscolo.ch.cam.ac.uk/zyggregator.php.RESULTS
Characterization of mutations that inhibit
the toxicity of E22G Ab42 and enhance the toxicity
of Ab40 in Drosophila
The E22G mutation in Ab42 is associated with an inherited,
early-onset form of AD (19). E22G Ab42 is highly
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FIGURE 1 Measuring the neurotoxicity of Ab mutants by their effect on
fly longevity. (A) The average neurotoxicity (Stox) of a single line of flies
expressing E22G Ab42 (B) compared with that of two independent lines
of flies expressing I31E/E22G Ab42 (, and >), one line of WT Ab40
(D), and one line of WT Ab42 (þ). (B) The average neurotoxicity of a single
line of flies expressingWTAb40 (B) or WT Ab42 (>) compared with those
of two independent lines of flies expressing E3R Ab40 (, and D); 100 flies
divided equally into 10 tubes were analyzed for each line. Stox for each tube
(n ¼ 10 flies per tube) was calculated from the median survival determined
by Kaplan-Meier survival analysis (see Materials and Methods). Differences
between lines (n ¼ 10 tubes) were analyzed for significance using the Mann
Whitney U-test (*p < 0.05, **p < 0.01, and ***p < 0.001).
TABLE 1 Predicted aggregation propensity scores
Zagg Score Zpf Score
E22G Ab42 1.11 0.65
I31E/E22G Ab42 1.10 0.51
Ab42 0.97 0.39
Ab40 0.94 0.37
E3R Ab40 0.96 0.41
Zagg: The propensity, calculated from the physicochemical properties of the
constituent amino acids, of the peptide to aggregate into amyloid fibrils.
Zpf: The propensity, calculated from the physicochemical properties of the
constituent amino acids, of the peptide to form prefibrillar aggregates.
See Materials and Methods for details of how Zagg and Zpf are calculated.
Probing Neurotoxic Aggregate Formation 1679aggregation-prone in vitro, and its expression in the central
nervous system of D. melanogaster results in severe neuro-
degeneration manifested by a 74% reduction in longevity
(Stox ¼ 0.745 0.01; see Materials and Methods for the defi-
nition of Stox; Fig. 1 a (20)) compared to flies expressing the
nontoxic Ab40 peptide (Stox ¼ 0.00 5 0.01). In an earlier
study (15), we identified a single-point mutant of E22G
Ab42 (I31E/E22G Ab42) that, in stark contrast, resulted in
no significant signs of neurodegeneration when expressed
in two independent lines of Drosophila (I31E/E22G Ab42
Stox ¼ 0.01 5 0.03 for line 1, Stox ¼ 0.01 5 0.04 for line
2; Fig. 1 a); indeed, their behavior was indistinguishable
from that of flies expressing Ab40. This result was repro-duced in four other independent lines of D. melanogaster ex-
pressing I31E/E22G Ab42 (15).
Given that this single-point mutation is able to effectively
abolish the neurotoxicity of E22G Ab42, we hypothesized
that it must also be possible to convert the Ab40 peptide,
which is much less prone to aggregate than E22G Ab42 (or
indeed WT Ab42 itself) and is normally harmless in our
Drosophila model, into a neurotoxic peptide through the
alteration of a single amino acid. While investigating a
number of single-point mutants of Ab40, we found that the
E3R mutant, when expressed in the central nervous system
of two independent lines of D. melanogaster, reduced the
longevity of the flies by ~30% (Stox E3R Ab40 ¼ 0.29 5
0.08 for line 1 and 0.37 5 0.08 for line 2) as compared to
flies expressing the nontoxic Ab40 (Stox ¼ 0.00 5 0.01;
Fig. 1 b). Indeed, the E3R mutation renders the Ab40 as
damaging to the brain as the WT Ab42 peptide (Stox ¼
0.36 5 0.01; Fig. 1 b) that is primarily responsible for
causing neurodegeneration in the brains of patients with
AD. This result was reproduced in four other independent
lines of D. melanogaster expressing E3R Ab40, each of
which has median survival rates significantly shorter than
that of Ab40-expressing flies.
I31E and E3R mutations do not alter the in vitro
ThT binding kinetics of E22G Ab42 and Ab40
From an analysis of their physicochemical properties, neither
the I31E mutant of E22G Ab42 nor the E3R mutant of Ab40
are predicted to significantly alter the propensity of their
respective parent peptides to form b-sheet-rich aggregates,
as both I31 and E3 are located within regions of the polypep-
tide chain that have a low aggregation propensity and there-
fore are not rate-limiting for aggregation (Table 1; see
Fig. 5). Moreover, we confirmed that prediction experimen-
tally by monitoring the kinetics of aggregation using
a ThT fluorescence assay and TEM (kagg E22G Ab42 ¼
0.19 5 0.08 min1 and kagg E22G/I31E Ab42 ¼ 0.10 5
0.02 min1; Fig. 2, a, c, and d) (15)).
To determine experimentally whether the E3R Ab40
peptide also aggregates at a rate similar to that of its parent
peptide, WT Ab40, we measured the aggregation rates of
these two peptides, again using ex situ ThT fluorescenceBiophysical Journal 98(8) 1677–1684
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FIGURE 2 Measurement of the kinetics of aggregation and the types of
aggregates formed by Ab40, E22G Ab42, and their mutants. (A) Progression
of the aggregation reactions for E22G Ab42 (solid circles) and E22G/I31E
Ab42 (open circles)monitored byThTfluorescence spectroscopy. (B) Thepro-
gression of the aggregation reactions for Ab40 (solid squares) and E3R Ab40
(open squares) was monitored by ThT fluorescence spectroscopy. (C and D)
Transmission electron micrographs of samples from the end points of the
E22G Ab42 and I31E/E22G Ab42 aggregation reactions shown in A indicate
that fibrils were formed by both peptides. (E and F) Transmission electron
micrographs of samples from the end points of the Ab40 and E3RAb40 aggre-
gation reactions shown in B indicate that fibrils were formed by both peptides.
Scale bar ¼ 200 mm.
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1680 Brorsson et al.and TEM imaging. The E3R Ab40 and WT Ab40 peptides
can be seen to aggregate to states that bind ThT and have
a fibrillar appearance at very similar overall rates (kagg
Ab40 ¼ 0.0345 0.01 min1 and kagg E3R Ab40 ¼ 0.0375
0.01 min1; Fig. 2, b, e, and f), again in accord with our
predictions (Table 1). The growth of Ab40 aggregates, how-
ever, is preceded by a significant lag phase that is notably
absent in the aggregation of the E3R Ab40 peptide. This
suggests that the early stages of aggregation, unlike the later
growth phase, differ significantly for these two peptides
under the conditions described here. Of note, the TEM
images reveal that larger amounts of prefibrillar species
and lower quantities of fibrils are present in the E22G
Ab42 and E3R Ab40 samples (Fig. 2, c and f) relative to their
respective counterparts (Fig. 2, d and e). This is further
investigated in the following section.Effects of the I31E and E3R mutations
on the morphology of the aggregates formed
by E22G Ab42 and Ab40
It is well established that Ab peptides, like other amyloido-
genic peptides and proteins, can form a host of prefibrillar
aggregates in vitro before the formation of mature amyloid
fibrils. These species range in size from dimers to large pro-
tofibrillar assemblies visible by TEM in vitro (14,21). Such
species have also been detected in transgenic models of
AD (13,22) and in postmortem tissue from the brains
of patients with AD (14,23). In both cases, the presence of
the prefibrillar aggregates has been shown to be correlated
with a decline in cognitive function, as well as with defects
in long-term potentiation and synaptic loss (24,25). There-
fore, it appears possible that the I31E mutation can substan-
tially reduce the neurotoxic properties of E22G Ab42 by
altering the balance between its relative propensities to
form prefibrillar and mature fibrillar aggregates without
significantly altering the overall rate at which the latter are
formed.
To investigate this possibility, we monitored and analyzed
the morphologies of the aggregates formed by both I31E/
E22G Ab42 and E22G Ab42 over the course of their forma-
tion. To visualize any oligomers that formed during the
course of experiments, both peptides were incubated without
agitation to avoid perturbing the nature of the population of
such intermediate species. In both cases, no aggregates were
detectable by TEM in the solutions examined immediately
after dissolution of the monomeric peptides in 50 mM
NaH2PO4 at pH 7.4 (Fig. 3, a and d). After 15 min, however,
spherical oligomers and short curvilinear prefibrillar aggre-
gates similar to those observed previously with E22G
Ab42 (19) were detectable by TEM (Fig. 3 b). With I31E/
E22GAb42, however, no such aggregates were observable
at the same time (Fig. 3 e). The absence of even small aggre-
gates of I31E/E22G Ab42 after 15 min was also confirmed by
analysis of the initial preparations of both peptides by SEC
GE22G Ab42 I31E/E22G Ab42
FIGURE 3 Time-course analysis by TEM of the aggregation of E22G
Ab42 and I31E/E22G Ab42. (A–C) TEM images taken throughout the aggre-
gation reaction of E22G Ab42 (t ¼ 0 min, 15 min, and 6 days, respectively).
(D–F) TEM images taken throughout the aggregation reaction of I31E/
E22G Ab42 (0 min, 15 min, and 6 days, respectively). Scale bar ¼ 200 nm.
(G) The size distributions of aggregates of E22G Ab42 (solid line) and
E22G/I31E Ab42 (dashed line) determined by SEC performed immediately
after dissolution of the peptides.
Probing Neurotoxic Aggregate Formation 1681(see Materials and Methods). Chromatograms of solutions of
the E22G Ab42 variant show two distinct peaks—one at
a size consistent with low-molecular-weight (LMW) Ab
species (potentially monomer, dimer, and trimer) and
another eluting in the void volume—indicating that the solu-
tion contained higher-molecular-weight but still soluble
aggregate species (Fig. 3 g). By contrast, the chromatograms
of the solution of I31E/E22G Ab42 at the same time points
show only a single LMW peak (Fig. 3 g).
Analysis of the E22G Ab42 sample by TEM after 6 days
reveals the presence of an abundance of short, curved proto-
fibrillar species and amorphous aggregates accompanied by
a small number of well-defined fibrils (Fig. 3 c). By contrast,
the I31E/E22G Ab42 contains mostly long, straight, mature
fibrils (Fig. 3 f), and no amorphous or structured prefibrillar
assemblies are detectable. These results indicate that the
I31E mutation in E22G Ab42 does indeed dramatically
reduce the propensity of E22G Ab42 to form prefibrillar
species relative to fibrillar species. Provided that such a situ-
ation occurs in vivo, this would provide an explanation for
the substantially reduced toxicity despite a similar overall
aggregation propensity.
To further test this hypothesis, we tested the effect of the
E3R mutation on the balance between the population of
fibrillar and prefibrillar species in Ab40 through a compara-
tive morphological analysis of the aggregates formed over
time in solutions of Ab40 and E3R Ab40, without agitation,
using TEM. In this study no aggregates could be detected
for Ab40 after one minute (Fig. 4 a) while at the correspond-
ing time point for E3R Ab40 abundant quantities of amor-
phous aggregates were detected (Fig. 4 d). SEC analysis
also showed the absence at this early time point of small
prefibrillar Ab40 species that are not detectable by TEM
(Fig. 4 g) as the peptide elutes as a single LMW peak.
Surprisingly, considering that prefibrillar aggregates are
visible after one minute by TEM, SEC analysis of E3R
Ab40 at this time also reveals only a LMW peak, suggesting
that the aggregates formed by this variant are relatively
unstable and dissociate during separation, or are retained
by the column.
After 3 days, long mature fibrils are visible for the
Ab40 peptide (Fig. 4 b), whereas the E3R Ab40 samples
are dominated by large numbers of small globular aggre-
gates (Fig. 4 e), with a short fibril being observed very
occasionally (Fig. 4 e, inset). From day 5 onward, fibrils
are the dominant species for both peptides, but they have
different morphologies. For Ab40 the fibrils are long and
very regular (Fig. 4 c), whereas the E3R Ab40 fibrils are
shorter and significantly irregular in appearance (Fig. 4 f).
These results indicate that the E3R mutation significantly
decreases the relative propensity of the Ab40 peptide to
form well-defined and inert fibrillar aggregates. This leads
to an enhanced population of oligomeric and other disor-
dered structures, which explains its enhanced toxicity rela-
tive to Ab40.Biophysical Journal 98(8) 1677–1684
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FIGURE 4 Time-course analysis by TEM of the aggregation of Ab40 and
E3R Ab40. (A–C) TEM images taken throughout the aggregation reaction for
WT Ab40 (1 min, 3 days, and 7 days, respectively). (D–F) TEM images
taken throughout the aggregation reaction for E3R Ab40 (1 min, 3 days,
and 7 days, respectively). Scale bar ¼ 200 nm. (G) The size distributions
of aggregates of Ab40 peptide (solid line) and E3R Ab40 (dashed line) deter-
mined by SEC performed immediately after dissolution of the peptides.
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1682 Brorsson et al.Rationalization of the relative propensity
of peptides and proteins to form preﬁbrillar
aggregates
As we showed in a previous work (6), and further demon-
strated here, it is possible to rationalize with a high degree
of accuracy the propensity of a given polypeptide sequence
to form b-sheet-rich aggregates in vitro (as measured here
by ThT fluorescence and TEM) by assessing the intrinsic
physicochemical properties of its constituent amino acids.
The algorithm (Zagg) we developed for this purpose takes
into account the charge, hydrophobicity, and secondary
structure propensities of each amino acid, and weights their
relative importance using available data from our work and
from the literature.
To rationalize the propensity of proteins such as Ab to
specifically form potentially toxic prefibrillar aggregates
during the process of amyloid aggregation, we developed
a second algorithm based on the same physicochemical prop-
erties but parameterized on the basis of aggregation-rate data
collected from an extensive study of mutational variants of
the muscle acylphosphatase protein (AcP), in which the
aggregation process (under the experimental conditions
used) culminates specifically in the formation of prefibrillar
rather than mature fibrillar assemblies (18). This second
algorithm (used previously (15) to generate the parameter
Ztox, here renamed Zpf) predicts both that I31E/E22G Ab42
has a lower propensity than E22G Ab42 to form prefibrillar
aggregates (Zpf I31E/E22G Ab42 ¼ 0.51; E22G Ab42 ¼
0.65), and E3R Ab40 has a higher propensity to form prefi-
brillar aggregates than WT Ab40 (Zpf E3R Ab40 ¼ 0.41;
WT Ab40 ¼ 0.37; Table 1).
In this regard, it is particularly striking that the E3R muta-
tion, which renders Ab40 as toxic to the fly brain as the WT
Ab42 peptide (Fig. 1 b), has a comparable propensity to form
prefibrillar aggregates (Zpf Ab42 ¼ 0.39). In summary, there-
fore, the various predictions for the propensities to form
different types of aggregates are consistent with the experi-
mental data presented here, and strongly implicate prefibril-
lar aggregates as the primary neurotoxic agents, at least in
this Drosophila model of AD. These findings are highly
consistent with those obtained in many other systems indi-
cating that the most highly toxic species associated with
amyloid formation are likely to be small aggregates with
high surface/volume ratios (26,27).DISCUSSION
In this study, we investigated two pairs of mutational vari-
ants of Ab: one from the early-onset, disease-related E22G
Ab42 peptide, and one from the Ab40 peptide, which is nor-
mally harmless in our model system. Each pair was chosen
by a rational design strategy to ensure that both members
had similar overall propensities to form fibrillar aggregates
in vitro but very different neurotoxic properties in vivo in
Probing Neurotoxic Aggregate Formation 1683our Drosophila model. We rationalized the different
behavior of the two peptides in each of these pairs by iden-
tifying significant differences in their relative propensities to
form prefibrillar aggregates in vitro during the process of
aggregation into mature fibrils. In itself, this study shows
that single-point mutations can strongly modulate the aggre-
gation behavior and pathogenic properties of both peptides,
a phenomenon that is likely to be generic, i.e., to apply to
proteins and peptides generally. In addition, we derived an
algorithm that allows us to predict the effect of mutations
on both the fibrillar and prefibrillar states of proteins.
A variety of theoretical and experimental observations
suggest that aggregation into amyloid fibrils occurs by at
least a two-step mechanism in which monomeric polypeptide
chains that are either fully or partially unfolded nucleate and
condense into relatively disordered prefibrillar oligomeric
aggregates, and then reorganize into highly ordered fibrillar
structures with a cross-b structure (28,29). In agreement
with a range of other studies, this work demonstrates that
the morphologies of these two types of aggregates are clearly
distinct. It is therefore very likely that the specific nature of
the interactions, and the regions of the polypeptide chain that
are involved in forming these different structures will differ.
Furthermore, it is not surprising that amino acid substitutions
can affect different stages of the reaction in a different
manner, as we observed in this study, and that the propensi-
ties to form these different types of aggregates will differ to
some extent. It is particularly useful, therefore, that the algo-
rithms derived from experimental data appear capable of pre-
dicting the relative propensities to form the different types of
structure, and are robust and potentially widely applicable.
It is particularly interesting in the context of the factors
affecting these aggregation propensities that neither of the
two mutations discussed here (residues 3 and 31) is located
in a region of the Ab sequence that is predicted to have
a high propensity for aggregation (Fig. 5) or has been iden-
tified by solution and solid-state NMR studies to be in the
core region of the cross-b structure of the Ab fibrilFIGURE 5 Aggregation propensity profiles of Ab40 (solid line) and E22G
Ab42 (dashed line), indicating the locations in negative peaks of the two
mutants studied here (E3R Ab40 and I31E/E22G Ab40).(30,31). This observation is consistent with the finding that
neither mutation appears to affect the overall rate of fibril
formation (Fig. 2). The fact that both residues do, however,
influence the propensity to form prefibrillar aggregates is
consistent with the latter being formed through a relatively
disordered collapse of the polypeptide chain that must
involve a wider range of residues than those that are highly
structured in the conformation of the mature fibrils.
In support of these observations, we previously found that
regions of the amyloidogenic protein AcP, which are not
rate-limiting for the formation of protofibrillar aggregates,
can nonetheless contribute to their resistance to disaggrega-
tion, which again shows that different residues can play
a role at different stages of the aggregation process (32).
Furthermore, these results enable us to rationalize the recent
finding that mutations in the N-terminal region of Ab are
associated with familial AD, in that they can specifically
affect the propensity of the peptide to form prefibrillar and
potentially neurotoxic aggregates, as previously demon-
strated for familial AD mutations, such as E22G, that fall
within the highly aggregation-prone hydrophobic core of
Ab (33–35).CONCLUSIONS
We have shown through computational, in vivo, and in vitro
studies of mutational variants of the Ab40 and Ab42 peptides
that the sequence determinants of the formation of prefibril-
lar aggregates are related to but distinct from those that
control the rate at which a polypeptide chain assembles
into amyloid fibrils. The computational methods we used
to rationally alter the properties of the Ab peptides have
been shown to be applicable to many different proteins (5);
therefore, we propose that these distinctions are likely to
be relevant for future investigations of the wide range of
proteins that form amyloid fibrils. Furthermore, they may
enable us to understand why amyloid aggregation in some
cases results in the development of devastating neurological
diseases, and in other cases results in the formation of func-
tional, nonpathogenic amyloid fibrils in organisms such as
bacteria, yeast, and mammals (36–38).
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